A drug created by the company Biogen might be able to slow the progression of Alzheimer’s Disease.
The company initially discontinued work on aducanumab when it started with disappointing results. They now say that a further analysis of that same data has actually suggested it may decrease cognitive loss in its treatment of Alzheimer’s Disease.
Dr. Andrew Frank of Bruyère spoke about it yesterday on CFRA. Dr. Frank suggests further trials will be necessary, but that this remains a positive development in the world of dementia.